For research use only. Not for therapeutic Use.
Diflapolin is a highly active dual 5-lipoxygenase-activating protein (FLAP)/soluble epoxide hydrolase (sEH) inhibitor with marked anti-inflammatory efficacy and high target selectivity. Diflapolin inhibits 5-LOX product formation in intact human monocytes and neutrophils with IC50s of 30 and 170 nM, respectively, and suppressed the activity of isolated sEH (IC50=20 nM)[1].
Diflapolin (1-10 mg/kg; i.p.; 30 min before zymosan injection) exhibits potent anti-inflammatory properties in in-vivo experiments[1].
Catalog Number | I026126 |
CAS Number | 724453-98-9 |
Synonyms | 1-[4-(1,3-benzothiazol-2-ylmethoxy)-2-methylphenyl]-3-(3,4-dichlorophenyl)urea |
Molecular Formula | C22H17Cl2N3O2S |
Purity | ≥95% |
InChI | InChI=1S/C22H17Cl2N3O2S/c1-13-10-15(29-12-21-26-19-4-2-3-5-20(19)30-21)7-9-18(13)27-22(28)25-14-6-8-16(23)17(24)11-14/h2-11H,12H2,1H3,(H2,25,27,28) |
InChIKey | FGXLEECGXSDIMM-UHFFFAOYSA-N |
SMILES | CC1=C(C=CC(=C1)OCC2=NC3=CC=CC=C3S2)NC(=O)NC4=CC(=C(C=C4)Cl)Cl |
Reference | [1]. Garscha U, et al. Pharmacological profile and efficiency in vivo of diflapolin, the first dual inhibitor of 5-lipoxygenase-activating protein and soluble epoxide hydrolase. Sci Rep. 2017;7(1):9398. Published 2017 Aug 24. |